PUBLICATIONS IN PEER REVIEWED JOURNALS
2008
Bjarnason A, Adler SN, Bjarnason I. Probiotic prophylaxis in predicted severe acute pancreatitis. Lancet. 2008 12;372:114-115.
Björnsson E, Westgaard G, Bjarnason I. Severe injury to the small bowel associated with a short course of diclofenac.Scand J Gastroenterol. 2008;43:759-760
Johnson MW, Maestranzi S, Duffy AM, Dewar DH, Forbes A, Bjarnason I, Sherwood RA, Ciclitira P, Nicholls JR. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol. Mar;20:174-179
Bjarnason I. Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon. J R Soc Med. 2007;100 Suppl 48:11-14
Adler SN, Bjarnason I,Metzger YC. New balloon-guided technique for deep small-intestine endoscopy using standard endoscopes. Endoscopy. 2008;40:502-505
Johnson MW, Maestranzi S, Duffy AM, Dewar DH, Forbes A, Bjarnason I, Sherwood RA, Ciclitira P, Nicholls JR. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol. 2008;20:174-179.
2007
Bjarnason I. Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon. J R Soc Med. 2007;100 Suppl 48:11-4.
Loganayagam A, Bjarnason I. Stool tests: Are they useful? In Tozun N, Mantzaris G, Dagli U, Scholmeric J. IBD 2007-Achievements in reseach and clinical practice. Falk Syposium 159. Springer , Dordrecht, 2007:129-142
Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200
Leung WK, Bjarnason I, Wong VW, Sung JJ, Chan FK.
Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet. 2007;369:614.
Jacob M, Foster R, Sigthorsson G, Simpson R, Bjarnason I. Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch Toxicol. 2007;81:291-298
Leung WK, Bjarnason I, Chan FK. Low- dose aspirin and small bowel enteropathy Lancet. 2007;369:1691.
Culkin A, Gabe SM, Bjarnason I,
Grimble G, Madden AM, Forbes A. A double-blind, randomized, controlled
crossover trial of glutamine supplementation in home parenteral
nutrition. Eur J Clin Nutr. 2007
Adebayo D, Popat R, Thjodleifsson B, Bjarnason I. Granulomatous ileitis in a patient with ankylosing spondylitis. Nat Clin Pract Gastroenterol Hepatol. 2007;4:347-351
Bjarnason I, Scarpignato C,
Takeuchi K, Rainsford KD. Determinants of the short-term gastric damage
caused by NSAIDs in man. Aliment Pharmacol Ther. 2007;26:95-106
Thjodleifsson B, Geirsson AJ, Bjornsson S, Bjarnason I.
A common genetic background for inflammatory bowel disease and
ankylosing spondylitis: A genealogic study in Iceland. Arthritis Rheum.
2007 30;56:2633-2639
Maiden L, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, Bjarnason I.
Long-Term Effects of Nonsteroidal Anti-Inflammatory Drugs and
Cyclooxygenase-2 Selective Agents on the Small Bowel: A Cross-Sectional
Capsule Enteroscopy Study. Clin Gastroenterol Hepatol. 2007
Bjarnason I, Scott D. NSAIDs
and COX-2 selective agents: cause or cure of pain in IBD. In Clinical
dilemmas in Inflammatory Bowel Disease. Irving P, Rampton D, Shanahan F
(eds). Blackwell Publishing, Oxford. 2006:136-138
Bjarnason I. The impact of
recent data on our understanding of the roles of COX-1 and COX-2 in
gastrointestinal physiology. Clinical Drug Investigation 2007;27 (suppl
1):7-13
Bjarnason I. Alcohol: A friend or foe of IBD. Scand J Gastroenterol. 2007;42:899-901
2006
Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I.
Prevalence and Mechanism of Nonsteroidal Anti-Inflammatory Drug-Induced
Clinical Relapse in Patients With Inflammatory Bowel Disease. Clin
Gastroenterol Hepatol. 2006;4:196-202.
Kalaitzakis E, Johansson JE, Bjarnason I, Bjornsson E. Intestinal permeability in cirrhotic patients with and without ascites. Scand J Gastroenterol. 2006;41:326-30.
Fraser JS, King AL, Ellis HJ, Moodie SJ, Bjarnason I, Swift J, Ciclitira PJ. An algorithm for family screening for coeliac disease. World J Gastroenterol. 2006;12:7805-7809
Adebayo D, Bjarnason I. Is
non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more
important than NSAID gastropathy? Postgrad Med J. 2006;82:186-191.
Manoj K, Sigurbjornsson FT, Bjarnason I. Leucocyte apheresis for ulcerative colitis: Where do we stand? Dig Liver Dis. 2006
Ladwa M, Takeuchi K, Bjarnason I. Non-steroidal anti-inflammatory drugs request parity with Helicobacter pylori. Scand J Gastroenterol. 2006;41:373-375
Maiden L, Bjarnason. Capsule Enteroscopy and Crohn's Disease. Clin Gastroenterol Hepatol. 2006;4:660
Bjarnason I, Adler SN, Maiden L. Physical-chemical small bowel injury. In Keuchil M, Hagenmuller, Fleischer DE eds. Atlas of video capsuleendoscopy. Springer Medizin Verlag, Heidelberg 2006:144-148.
Bjarnason I Takeuchi K, Hanai H, Suzuki Y, Maiden L, Saniabadi AR.
Selective leucocytapheresis for inflammatory bowel disease: does this spare
corticosteroids? In Bianchi-Porro G, Bosani M, Pastor L eds. La gastropatia
da FANS: dopo il caso Vioxx. La colitie ulcerosa: progressi therapeutici.
Edizoni Liberia Cortina Verona 2006:81-91
2005
Atanasova BD, Li AC, Bjarnason I, Tzatchev KN, Simpson RJ. Duodenal ascorbate and ferric reductase in human iron deficiency. Am J Clin Nutr. 2005;81:130-133.
Takeuchi K, Bjarnason I, Laftah
AH, Latunde-Dada GO, Simpso RJ, Mckie AT. Expression of iron absorption
genes in mouse large intestine. Scand J Gastroenterolo 2005;40:169-177
Weller C, Oxlade N, Dobbs SM, Dobbs RJ, Charlett A, Bjarnason I. Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunology and Medical Microbiology.
2005;44:129-135
Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. Quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172-1178.
Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito
Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M,
Beretta A, Bjarnason I,
Lofberg R. Adacolumn for selective leukocytapheresis as a
non-pharmacological treatment for patients with disorders of the immune
system: An adjunct or an alternative to drug therapy? J Clin Apheresis.
2005;20:171-184
Dobbs RJ, Dobbs SM, Weller C, Bjarnason IT,
Oxlade NL, Charlett A, Al-Janabi MA, Kerwin RW, Mahler RF, Price AB.
Role of chronic infection and inflammation in the gastrointestinal
tract in the etiology and pathogenesis of idiopathic parkinsonism. Part
1: eradication of Helicobacter in the cachexia of idiopathic
parkinsonism. Helicobacter. 2005;10:267-275.
Bjarnason IT, Charlett A, Dobbs
RJ, Dobbs SM, Ibrahim MA, Kerwin RW, Mahler RF, Oxlade NL, Peterson DW,
Plant JM, Price AB, Weller C. Role of chronic infection and
inflammation in the gastrointestinal tract in the etiology and
pathogenesis of idiopathic parkinsonism. Part 2: response of facets of
clinical idiopathic parkinsonism to Helicobacter pylori eradication. A
randomized, double-blind, placebo-controlled efficacy study.
Helicobacter. 2005;10:276-287
Weller C, Charlett A, Oxlade NL, Dobbs SM, Dobbs RJ, Peterson DW, Bjarnason IT.
Role of chronic infection and inflammation in the gastrointestinal
tract in the etiology and pathogenesis of idiopathic parkinsonism. Part
3: predicted probability and gradients of severity of idiopathic
parkinsonism based on H. pylori antibody profile. Helicobacter.
2005;10:288-297.
Bjornsson E, Cederborg A, Akvist A, Simren M, Stotzer PO, Bjarnason I.
Intestinal permeability and bacterial growth of the small bowel in
patients with primary sclerosing cholangitis. Scand J Gastroenterol.
2005;40:1090-1094
Bjarnason I, Thjodleifsson B. The murky world of COX-2 selective agents. Immunopharmacology. 2005;13:381-393 Bjarnason I, Bjarnason A. Unorthodox treatment for irritable bowel syndrome? Eur J Gastroenterol Hepatol. 2005;17:1-3.
Takeutchi K, Adler SN, Bjarnason I. Nonsteroidal antiinflammatory
drug-induced small and large bowel damage. In Bayless TM, Diehl AM.
Advanced therapy in Gastroenterology and liver disease. BC Decker Inc,
Hamilton 2005;364-366
Bjarnason I, Takeuchi K, Maiden
L, Adler S. Drug-induced changes to the small and large intestine. In
Clinical Gastroenterology and Hepatology. Eds: Weinstein WM, Hawkey CJ,
Bosch J. Elsvier Mosby, Spain. 2005: 485-490
Bjarnason I, Biossoli F,
Conforti A, Maiden L, Moore N, Moretti U, Rainsford KD, Takeutchi K,
Velo GP. Adverse reactions and their mechanisms for nimesulide. In:
Nimesulide – Actions and uses. Rainsford KD (ed). Birkhouser Verlag,
Basel 2005:315-415
Bjarnason I, Maiden L, Takeuchi
K. Testing the gut and its function – faecal samples – breath tests and
more? In: Gastroenterology yesterday, today, tomorrow: A review and
preview. Eds: Adler G, Blum AL, Blum HE, Leuschner U, Manns MP, Mossner
J, Sartor RS, Scholmeric J. Falk symposium 144, Springer, Dordreich,
The Netherlands 2005:253-266
2004
Takeuchi K, Ladwa M, Bjarnason I. Fecal Calprotectin and IBD-A viewpoint. IBD Monitor 2004;5:91-95
Premchand P, Takeuchi K, Bjarnason I. Selective bloodletting for severe ulcerative colitis. Scand J Gastroenterol. 2004;39:416-417
Walley M, Hotz-Behofsits C, Simpson R, Bjarnason I. Nitric oxide: potential role for reducing gastro-enteropathy. Inflammopharmacology. 2003;11:429-436.
Jonzon B, Bjarnason I, Hawkey
C, Jones J, Goddard A, Fagerholm U, Karlsson P. The CINOD, AZD3582,
exhibits an improved gastrointestinal safety profile compared with
naproxen in healthy volunteers. Inflammopharmacology. 2003;11:437-444
Finkel Y, Bjarnason I, Lindblad
A, Lange S. Specially processed cereals: a clinical innovation for
children suffering from inflammatory bowel disease? Scand J
Gastroenterol. 2004 Jan;39:87-88
Premchand P, Takeuchi K, Bjarnason I. Macrophage, monocyte apheresis for refractory ulcerative proctitis. Eur J Gastroenterol Hepatol. 2004;16:943-945.
Bjarnason I, Takeuchi K, Bjarnason A, Adler SN, Teahon K. The G.U.T. of gut. Scand J Gastroenterol. 2004;39:807-815
.Smale S, Forgacs I, Bjarnason I. Protein losing enteropathy. In Encyclopedia of Gastroenterology. Elsevier 2004:251-254
Maiden L, Bjarnason I. COX 2 inhibition and bowel strictures.
Gut. 2004;53:1057-1058
Takeuchi K, Meera L, Bjarnason I.
Predictive factors of the course and therapeutic response in
inflammatory bowel disease. In Lukas M, Manns MP, Spicak J, Stange EF
eds. Immunological diseases of liver and gut. Kluver Academic
Publishers, Dordrecht. 2004:234-246
Johnson MW, Dewar DH, Ciclitira P, Forbes A, Nicholls RJ, Bjarnason I.
Use of fecal lactoferrin to diagnose irritable pouch syndrome: A word of caution. Gastroenterology. 2004;127:1647-1648
Takeuchi K, Maiden L, Bjarnason I.
Genetic aspects of intestinal permeability in inflammatory bowel
disease. In Inflammatory Bowel Disease: Crosseroads of microbes.
Epithelium and immune system. Novartis Foundation Symposium 263. John
Wiley & Sond, Ltd. Chichester 2004: 151-163
Takeuchi K, Maiden L, Bjarnason I. Genetic aspects of intestinal permeability in inflammatory bowel disease. Novartis Found Symp. 2004;263:151-158
2003
Hanai H, Watanabe F, Takeuchi K, Lida T, Tamada M, Iwaoka Y, Sanibadin
A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I.
Leukocyte adsorptive apheresis for the treatment of active ulcerative
colitis: a prospective, uncontrolled, pilot study. Clinical
Gastroenterol Hepatol 2003;1:28-35
Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I,
Gudbjartsson DF, Kristleifur Kristjansson, Meddings JB, Gudnason V,
Wandall JH, Andersen LP, Sherwood R, Kjeld M, Oddsson E, Gudjonsson H, Bjarnason I.
Subclinical intestinal inflammation: An inherited abnormality in
Crohn’s disease relatives? Gastroenterology 2003;124:1728-1737
Sanibadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Addachi T, Shima C, Bjarnason I,
Lofberg R. Adacolumn, an adsorption carrier based granulocyte and
monocyte apheresis devise tor the treatment of inflammatory and
refractory diseases associated with leukocytes. Therap Apher Dial
2003;7:48-59
Mukhin NA, GuliaevSV, Krivosheev OG, Semenkova EN, Kogan EA, Okhotnikhova NL, Zavodnov VIa, Gmoshinskii IV, Mazo VK, Crane R, Bjarnason I.
Clinical and prognostic value of lesions in the gastrointestinal tract
in systemic vascular purpura. Ter Arkh. 2003;75:50-54.
Smale S, Bjarnason I, Forgacs
I, Prasad P, Mukhood M, Wong M, Ng A, Mulcahy HE. Upper
gastrointestinal endoscopy performed by nurses: scope for the
future?Gut. 2003;52:1090-1094.
Hotz-Behofsits CM, Walley MJ, Simpson R, Bjarnason I. COX-1, COX-2 and the topical effect in NSAID-induced enteropathy. Immunopharmacology 2003;
Bjarnason I, Takeuchi K, Simpson R. NSAIDs: the Emperor’s new dogma? Gut 2003;52:1376-1378
Smale S, Bjarnason I. Determining small bowel integrity following drug treatment. Br J Clin Pharmacol. 2003;56:284-291.
Hawkey JC, Jones IJ, Atherton CT, Slelly MM, Bebb JR, Fagerholm U, Jonzon B, Karlson P, Bjarnason IT.
Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric
oxide donator: proof of concept study in humans. Gut 2003;52:1537-1542
Bjarnason I, Helgason KO,
Geirsson AJ, Sigthorsson G, Reynisdottir I, Gudbjartsson D,
Einarsdottir AS, Sherwood R, Kristjansson K, Kjartansson O,
Thjodleifsson B. Subclinical intestinal inflammation and sacroiliac
changes in relatives of patients with ankylosing spondylitis.
Gastroenterology 2003;125:1598-1605
Hotz-Behofsits CM, Walley MJM, Simpson R, Bjarnason IT. COX-1,COX-2 and the topical effect in NSAID-induced enteropathy. Immunopharmacology 2003;11:363-370
Bjarnason I. Innovative technologise – Capsule endsocopy. IAP Bulletin 2003:4-5
2002
Somasundaram S, Simpson R, Rafi S, Shergill J, Bjarnason I,
Wrigglesworth J. 2,4-Diamino-6-hydroxy pyrimidine inhibits
NSAID-induced nitrosyl-complex EPR signals and ulcer in rat jejunum.
BMC Gastroenterology 2002;2:8
Jacob M, Bjarnason I, Simpson RJ. Effects of indomethacin on energy metabolism in rat jejunal tissue in vivo. Clin Sci 2002;102:541-546
Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I. COX-1 and 2, intestinal integrity and pathogenesis of NSAID-enteropathy in mice. Gastroenterology 2002;122:1913-1923
Bridger S, Lee JCW, Bjarnason I,
Lennard Jones JE, Macpherson AJ. In sibblings with similar
susceptibility for inflammatory bowel disease, smokers tend to develop
Crohn’s disease and non-smokers ulcerative colitis. Gut 2002;51:21-25
Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I.
Use of surrogate markers of inflammation and Rome criteria to
distinguish organic from nonorganic intestinal disease.
Gastroenterology. 2002;123:450-460.
Taylor RM, Bjarnason I,
Cheeseman P, Davenport M, Baker AJ, Mieli-Vergani G, Dhawan A.
Intestinal permeability and absorptive capacity in children with portal
hypertension. Scand J Gastroenterol. 2002;37:807-811.
Thjodleifsson B, Davidsdottir K, Agnarsson U, Sigthorsson G, Kjeld M, Bjarnason I. Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine. Gut. 2002;51:816-817
Bjarnason I, Menzies IS. Causes
and consequences of altered gut permeability. In Brostoff J,
Challacombe S (eds). Food allergy and intolerance (2nd edition).
Saunders, Elsevier Science, London, 2002:241-257
Bjarnason I, Cederborg A,
Akvist A, Smale S. Intestinal barrier function. In Biology of the
intestine in growing animals. Zabielski R, Gregory PC, Westrom B (eds).
Elsevier, Amsterdam 2002:657-693
2001
Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, Gudjonsson H, Oddson E, Price AB, Fitzgerald DJ, Bjarnason I.
Selective inhibition in humans of COX-2 is associated with less
gastrointestinal injury: a comparison of nimesulide and naproxen. Gut
2001;48:339-348
Tibble J, Sigthorsson G, Foster R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood testing in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402-408
Jacob M, Bjarnason I, Rafi S,
Wrigglesworth J, Simpson RJ. A study of the effects of indomethacin on
liver mitochondria from rats, mice and humans. Aliment Pharmacol Ther
2001;15:1837-1842
Jacob M, Bjarnason I, Simpson R. Effect of indomethacin on energy metabolism in the rat and human jejunal tissue in vitro. Clin Sci 2001;101:493-498
Smale S, Natt RS, Orchard T, Russell AS, Bjarnason I. Spondylarthropathy and inflammatory bowel disease. Arthr Rheumat 2001;44:2728-2736
Tibble J, Sigthorsson G, Caldwell C, Palmer RH, Bjarnason I. Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats. Aliment Pharmacol Ther 2001;15:2001-2008
Bjarnason I. Enteric coating of
mycophenolate sodium: a rational approach to limit gastrointestinal
lesions and extend the therapeutic index of mycophenolate. Trasnsplant
Proc. 2001;33:3238-3240
Smale S, Bjarnason I.
Nonsteroidal antiinflammatory drugs, enterocolonic ulceration, and
inflammatory bowel disease. In Bayless TM, Hanauer SB eds. Advanced
therapy of inflammatory bowel disease. BC Decker, Hamilton. 2001:625-629
Bjarnason I, Rainsford KD. COX-2 inhibitors and the gastrointestinal tract. Gut 2001;48:451
Tibble J, Bjarnason I. Faecal calprotectin as an index of intestinal inflammation. Drugs Today; 2003;37:85-96
Bjarnason I, Sherwood R. Faecal
calprotectin: a significant step in the noninvasive assessment of
intestinal inflammation. J Pediatr Gastroenterol 2001;33:11-13
Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7:460-465
Smale S, Tibble J, Sigthorsson G, Bjarnason I.
Epidemiology and different diagnosis of NSAID-induced injury to the
mucosa of the small bowel. Best Pract Res Clin Gastroenterol
2001;15:721-738
Bjarnason I, Rainsford KD. Are cyclo-oxygenase-2 inhibitors free of gastrointestinal side effects? West J Med 2001;175:267-268
2000
Somasundaram S, Sigthorsson G, Simpson R, Watts J, Jacob M, Tavares IA, Rafi S, Roseth A, Foster R, Price AB, Wrigglesworth JM, Bjarnason I.
Uncoupling of intestinal mitochondrial oxidative phosphorylation and
inhibition of cyclooxygenase are required for the development of
NSAID-enteropathy in the rat. Aliment Pharmacol Ther 2000;14:639-650
Taylor C, Hodgson K, Sharpstone D, Sigthorsson G, Coutts M, Sherwood R, IMenzies IS, Gazzard B, Bjarnason I.
The prevalence and severity of intestinal disaccharidase deficiency in
HIV-infected subjects. Scand J Gastroenterol 2000;35:599-606
Sigthorsson G, Tibble J, Mahmud T, Bjarnason I.
NSAID-induced gastrointestinal damage: the biochemical consequences of
the “ion trapping” hypothesis. Immunopharmacology 2000;8:31-41
Tibble J, Sigthorsson G, Bridger S, Fagerhol M, Bjarnason I.
Surrogate markers of intestinal inflammation are predictive of relapse
in patients with inflammatory bowel disease. Gastroenterology
2000;119:15-22
Thomas P, Rihani H, Roseth A, Sigthorsson G, Price A, Nicholls RJ, Bjarnason. Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum. 2000;43:214-220
Tibble JA, Sigthorsson G, Foster R, Bjarnason I.
Comparison of the intestinal toxicity of celecoxib, a selective COX-2
inhibitor, and indomethacin in the experimental rat. Scand J
Gastroenterol 2000;35:802-807
Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-513
Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Boognese J, Bjarnason I.
COX-2 inhibition with rofecoxib does not increase intestinal
permeability in healthy subjects: a double blind crossover study
comparing rofecoxib with placebo and indomethacin. Gut 2000;47:527-532
Borrelli F, Welsh NJ, Sigthorsson G, Simpson R, Palizban A, Bjarnason I, Tavares IA. Gastric acid secretion in cyclooxygenase-1 deficient mice. Alim Pharmacol Therap 2000;14:1365-1370
Sigthorsson G, Thjodleifsson B, Mahmud T, Bjarnason I.
Gastrointestinal tolerability of nimesulide, a selective
cyclooxygenase-2 inhibitor, in experimental animals and man.
Immunopharmacology 2000;8:175-187
Tibble J, Forgacs I, Bjarnason I, Przemioslo R. The effects of a pre-assessment clinic on nonattendance rates for day-case surgery. Endoscopy 2000;32:963-965
Smale S, Tibble J, Bjarnason I. Small intestinal permeability. Curr Oppin Gastroenterol 2000;16:134-139
Tibble J, Smale S, Bjarnason I. Value of intestinal function tests in inflammatory bowel disease. Infl Bowel Dis Monitor 2000;1:99-103
1999
Sharpstone D, Neild P, Crane R, Taylor C, Abraham H, Gazzard B, Bjarnason I.
Gastric emptying, and small bowel transit, absorption and permeability
in AIDS patients with and without diarrhoea. Gut 1999;45:70-76
Murphy B,Taylor C, Crane C, Kizza A, Bjarnason I.
A comparison between intestinal function in hiv seropositive patients
in Kampala and London. Scand J Gastroenterol 1999;34:491-495
D'Antiga L. Dhawan A, Davenport M, Mieli-Vergani G, Bjarnason I. Intestinal absorption and permeability in paediatric short bowel syndrome. J Paed Gastroenterol Nutr 1999;29:588-593
Tibble JA, Foster R, Sigthorsson G, Scott D, Roseth A, Bjarnason I. Faecal calprotectin: A simple method for the diagnosis of NSAID-induced enteropathy. Gut 1999;45:362-366
Bjarnason I, Thjodleifsson B.
Gastrointestinal toxicity of NSAIDs: the effect of nimesulide compared
with naproxen on the human gastrointestinal tract. Rheumatology 1999;38
(sullp I):24-32
Bjarnason I. Bjarnason I. Forthcoming NSAIDs: Are they really devoid of side effects. Ital J Gastroenterol & Hepatol. 1999;31(Suppl. 1):S27-36
Macpherson AJS, Maloy KJ, Bjarnason I. Intolerance of the dirty intestines. Gut 1999;44:774-775
Bjarnason I, Menzies IS. Causes
and consequences of altered intestinal permeability. In: Brostoff J,
Challacombe S (eds): Textbool of Food Allergy, second edition. WB
Saunders, London. In press.
Bjarnason I, Price AB. Small
intestinal inflammation, ulcers and strictures. In: Marsh MN (ed). The
small intestine. Blackwell Science, Boston. I
Bjarnason I. Prescribing NSAIDs: Intestinal toxicity and emerging safer anti-inflammatory drugs. CME Rheumatology & Arthritis.
Bjarnason I. Metabolic bone disease in patients with inflammatory bowel disease. Rheumatology 1999;38:801-804
Scarpignatio C, Bjarnason I,
Bretagne J.-F., De Pouvourville G, Garcia Rodrigues LA, Goldstein JL,
Muller P, Simon B. Towards a GI safer antiinflammatory therapy.
Gastroenterol Int 1999;12:186-214
Tibble J, Bjarnason I. Side-effects of drugs on the small intestine. Prescriber 1999;10:79-84.
Tibble J, Smale S, Bjarnason I. Adverse effects of drugs on the small bowel. Adverse Drug Reaction Bulletin. 1999; no 198:755-758
1998
Gabe S, Bjarnason I, Redger
JM, Toloughamari Z, Johnson PJ, Barkley GR, Williams R, Silk DBA. The
effects of tacrolimus on mitochondrial and intestinal barrier function.
Gastroenterology 1998: 115:67-74
Sigthorsson G, Jacob M, Wrigglesworth J, Somasundaram S, Tavares I, Foster R, Roseth A, Rafi S, Mahmud T, Simpson R, Bjarnason I.
Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2
inhibitor, on key pathophysiologic steps in the pathogenesis of
nonsteroidal anti-inflammatory drug enteropathy in the rat. Scand J
Gastroenterol 1998;33:728-735.
Sigthorsson G, Tibble J, Hayllar J, Menzies I, Macpherson A, Moots R, Scott D, Gumpel MJ, Bjarnason I. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998;43:506-511
Mahmud T, Somasundaram S, Sigthorsson G, Simpson RJ, Foster R, Tavares IA, Roseth A, Hutt AJ, Jacob M, Pacy J, Scott DL, Bjarnason I.
Enantiomers of flurbiprofen can distinguish key pathophysiological
steps of NSAID-enteropathy in the rat by stereoselective inhibition of
cyclooxygenase. Gut 1998;43:775-782
Gabe S, Jacob M, Bjarnason I.
The intestinal permeability barrier-what is measured, and what does it
mean? In: Gut and the liver. Blum HE, Bode Ch, Bode JCh, Sartor RB
(eds.). Falk Symposium No 100. Kluwer Academic Publishers, Dordrech
1998:31-46
Jacob M, Simpson R, Bjarnason I.
Nonsteroidal anti-inflammatory drugs, cyclooxygenase selectivity and
gastrointestinal toxicity. Ital J Gastroenterol & Hepatol.
1998;30:12-18
Bridger S, Bjarnason I.
Prescribing NSAIDs: recent insights into gastrointesatinal toxicity.
National Association of Fundholding Practices Year Book. 1998;5:135-141.
1997
Bjarnason I, Macpherson A,
Rothman H, Schupp J, Hayllar J. A randomised, double blind, crosseover
comparative endoscopy study on the gastroduodenal tolerability of a
highly specific cyclo-oxygenase-2 inhibitor, flosulide, and naproxen.
Scan J Gastroenterol 1997;32:126-130
Bjarnason I, Macpherson A,
Mackintosh C, Buxton-Thomass N, Forgacs I, Moniz C. Reduced bone
mineral density in patients with inflammatory bowel disease. Gut
1997;40:228-233
Somasundaram S, Rafi SS, Jacob M, Sigthorsson G, Mahmud T, Sherwood R, Price AB, Macpherson A, Scott D, Wrigglesworth JM, Bjarnason I. Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Gut 1997;40:608-613.
Sherwood R, Marsden JT, Stein CA, Somasundaram S, Aitken C, Oxford JS, Menzies IS, Bjarnason I. AZT absorption and small intestinal function in HIV infected subjects. J Antiviral Chemistry and Chemotherapy. 1997;8:327-332
Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I.
Mitochondrial damage: a possible mechanism of the "topical" phase of
NSAID-induced injury to the rat intestine. Gut 1997;41:344-353
Bjarnason I, Macpherson A,
Price AB. Non-steroidal anti-inflammatory drug-induced enteritis. In
Inflammatory bowel diseases (3 rd edition). Eds: Allan RN, Rhodes JM,
Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio VW. Churchill
Livingstone, New York. 1997:437-442
Bjarnason I. NSAIDs, COX and GI safety. Prescriber 1997; (suppl):4-6
Bjarnason I. The effects of nonsteroidal anti-inflammatory drugs on the small intestine: clinical implications. Arthritis care. 1997;6:1-4
1996
Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365-375
Teahon K, Somasundaram S, Smith T, Menzies I, Bjarnason I. Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. Gut 1996;38:864-869
Bjarnason I, Batt R, Catt S,
Macpherson A, Maxton D, Menzies IS. Evaluation of differential
disaccharide excretion in urine for non-invasive assessment of
intestinal disaccharidase activity caused by a-glucosidase inhibition,
primary hypolactasia and coeliac disease. Gut 1996;39:374-381
Bjarnason I, Sharpstone D,
Francis N, Marker A, Taylor C, Barrett M, Macpherson A, Baldwin C,
Menzies IS, Crane R, Smith T, Pozniak A, Gazzard B. Intestinal
inflammation, ileal structure and function in HIV. AIDS
1996;10:1385-1391
Mahmud T, Rafi S, Scott DL, Wrigglesworth JM, Bjarnason I. NSAIDs and uncoupling of oxidative phosphorylation. Arth Rheum 1996;39:1998-2003
Bjarnason I, Peters TJ.
Influence of anti-rheumatic drugs on gut permeability and on gut
associated lymphoid tissue. In Veys EM, Mielants H (eds). Gut
inflammation in rheumatology. Bailliers Clinical Rheumatology,
Bailliere Tindall, London. 1996:165-176
Mahmud T, Scott D, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996;55:211-213
Bjarnason I, Menzies I, Macpherson A. Pouch permeability: breaching barriers to understanding pouchitis? Gut 1996;39:338-339
Bjarnason I, Macpherson AJS. Intestinal absorption-permeability tests and nutrition. Clinical Nutrition 1996;5:63-66
Bjarnason I, Macpherson A.
Intestinal permeability: Tests for diagnostic leaks or leaky diagnostic
tests? Zeits Gastroenterol 1996;35 (suppl. 4):54-59
Bjarnason I. Intestinal
permeability and intestinal inflammation: Making sense out of the
facts. In Bjornsson OG (ed). Davids book. Icelandic University Press,
Reykjavik 1996:189-224
Bjarnason I, Hayllar J. Early pathogenic events in NSAID-induced gastrointestinal damage. Ital J Gastroenterol 1996;28 (sullp 4):19-22
Hayllar J, Bjarnason I. Gastroduodenal tolerability of a highly specific cyclo-oxygenase-2 inhibitor. Ital J Gastroenterol 1996;28 (Suppl 4):30-32
1995
Teahon K, Pearson M, Levi AJ, Bjarnason I. Practical aspects of elemental diets in patients with Crohn's disease. J Ent and Parent Nutr. 1995;19:365-368
Teahon K, Pearson M, Smith T, Levi AJ, Bjarnason I.
Alterations in nutritional status and disease activity during treatment
of Crohn's disease with elemental diet. Scand J Gastroenterol.
1995;30:54-60
Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: An overview. Gastroenterology. 1995;108:1566-1581
Shah K, Price AB, Talbot IC, Bardhan KD, Fenn CG, Bjarnason I.
The effect of long term misoprostol co-administration with nonsteroidal
anti-inflammatory drugs: a histological study. Gut: 1995;37:195-198
Somasundaram S, Hayllar J, Rafi S, Wrigglesworth JM, Macpherson AJS, Bjarnason I.
The biochemical basis of NSAID-induced damage to the gastrointestinal
tract: A review and a hypothesis. Scand J Gastroenterology.
1995;30:289-299
Khoo UY, Bjarnason I, Donaghy
A, Williams R, Macpherson A. Antibodies to colonic epithelial cells
from the serum and colonic mucosal washings in ulcerative colitis. Gut
1995;37:63-70
Shah K, Price AB, Talbot IC, Bardhan KD, Fenn CG, Bjarnason I.
Effect of long term misoprostol co-administration with non-steroidal
anti-inflammatory drugs: a histological study. Gut 1995;37:195-198
Mayall TP, Bjarnason I, Peters TJ, Macpherson AJM. Mitochondrial gene expression in small intestinal epithelial cells. Biochem J 1995;308:665-671
Keating J, Bjarnason I,
Somasundaram S, Macpherson A, Francis N, Price AB, Sharpstone D,
Smithson J, Menzies IS, Gazzard BG. Intestinal absorptive capacity,
intestinal permeability and jejunal histology in HIV and their relation
to diarrhoea. Gut 1995;37:623-629
Bjarnason I, Macpherson A,
Teahon K. The grand unification theory (GUT) of the pathogenesis of
small bowel disease and the relation to Crohn's disease. Focus on
Gastroenterology. Proceedings of Waltham/ESCG Symposia. 1995:18-25
Bjarnason I, Macpherson A, Menzies IS. Intestinal permeability: The basics. Can J Gastroenterol 1995;9:203-212
Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995;346:521-522
Bjarnason I, Macpherson A.
Alcohol and small intestinal permeability. In: Preedy VR, Watson RR
(eds). Alcohol and the gastrointestinal tract. CRC Press, Boca Ranton
1996:219-234.
Macpherson AJS, Bjarnason I. Basic science 1, clinical gastroenterology 0. Lancet 1995;346:S6
1994
Ohri SK, Somasundaram S, Koak Y, Macpherson A, Keogh BE, Taylor KM, Menzies IS, Bjarnason I.
The effect of intestinal hypoperfusion during cardiopulmonary bypass
surgery on saccharide permeation and intestinal permeability in man.
Gastroenterology 1994;106:318-323.
Hayllar J, Smith T, Macpherson A, Price AB, Gumpel MJ, Bjarnason I.
NSAID-induced small intestinal inflammation and blood loss; the effect
of sulphasalazine and other disease modifying drugs. Arthr Rheumat
1994; 37:1146-1150
Wicks C, Somasundaram S, Bjarnason I,
Menzies IS, Routley D, Potter D, Tan KC, Hayllar K, Williams R.
Comparison of enteral feeding and total parentral nutrition after liver
transplantation. Lancet: 1994;344:837-840
Bjarnason I, Maxton D, Reynolds
A, Catt S, Peters TJ, Menzies IS. A comparison of 4 markers of
intestinal permeability in control subjects and patients with coeliac
disease. Scand J Gastroenterol 1994;26:630-639
Teahon K, Webster D, Price AB, Weston J, Bjarnason I. Studies on the enteropathy associated with primary hypogammaglobulinaemia. Gut 1994;35:1244-1249
Bjarnason I, Macpherson A.
Treatment of nonsteroidal antiinflammatory drug induced damage to the
small and large intestine. In: Bayless TM, ed. Current Therapy in
Gastroenterology and Liver Disease (4 th ed). Mosby, St Louis 1994:
295-298
Macpherson AJS, Khoo UY, Bjarnason I. Inflammatory bowel disease of mice - and men. Lancet 1994;343:130-131.
Bjarnason I. Intestinal Permeability. Gut 1994; 35 (suppl 1):S18-S22.
Bjarnason I, Macpherson AJS. Intestianl toxicity of non-steroidal anti-inflammatory drugs. Pharmac Ther 1994;62:145-157.
Macpherson AJS, Bjarnason I. Colonocytes in Barrett's metaplasia. Lancet 1994;344:903-904.
Bjarnason I, Price AB. The
small and large intestinal pathologies of non-steroidal
anti-inflammatory drug ingestion. Ann Pathol 1994;14:326-332.
Bjarnason I, Macpherson A,
Menzies IS. Intestinal permeability: The basics. In: Sutherland LR,
Collins SM, Martin F, McLeod RS, Targan SR, Wallace JL, Williams CN
(eds). Inflammatory bowel disease. Basic research, clinical
implications and trends in therapy. Kluwer Academic Press, Dordrech.
1994:53-70.
Bjarnason I. The effects of
nonsteroidal antiinflammatory drugs on the small and large intestine.
Searle Litterature Review Series 1994;1, no 2: 1-15.
1993
Ohri SK, Bjarnason I, Pathi V,
et al. Cardiopulmonary bypass impairs small intestinal transport and
increases gut permeability. Ann Thorac Surg 1993;55:1080-1086.
Pearson M, Teahon K, Levi AJ, Bjarnason I. Food intolerance in patients with Crohn's disease. Gut 1993;34:783-787.
Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I.
Intestinal permeability in Crohn's disease and its relation to disease
activity and relapse following treatment with elemental diet. Eur J
Gastroenterol and Hepatol 1993;5:79-84.
Bjarnason I, Hayllar J,
Macpherson AJ, Russell AS. Side effects of nonsteroidal
anti-inflammatory drugs on the small and large intestine in humans.
Gastroenterology 1993;104:1832-1847.
Quinn CM, Bjarnason I, Price AB. Gastritis in patients on nonsteroidal anti-inflammatory drugs. Histopathology 1993;23:341-348.
Teahon K, Bjarnason I. Comparison of leucocyte excretion and blood loss in inflammatory disease of the bowel. Gut 1993;34:1535-1538.
Bardhan KD, Bjarnason I, Scott
DL, Griffin WM, Fenn GC, Shields MJ, Morant SV. The prevention and
healing of acute non-steroidal anti-inflammatory drug-associated
gastroduodenal mucosal damage by misoprostol. Br J Rheumatol
1993;32:990-995.
Macpherson AJ, Bjarnason I.
Danni intestinali da FANS. In: Guslandi M, Braga PC, ed. Danni da
farmaci all'apparato digerente. Berlin: Springer-Verlag, 1993: 77-88.
Bjarnason I, Macpherson AJS,
Somasundaram S, Teahon K. Non-steroidal anti-inflammatory drugs and
Crohn's disease. In: Scholmeric J, Kruis W, Goebbell H, Hohenberger W,
Gross V, (eds). Inflammatory bowel diseases:Pathophysiology as basis of
treatment.Falk Symposium No 67. Lancaster: Kluwer Academic Publishers,
1993:208-222.
Bjarnason I, Macpherson AJ. Delivery, safety and efficacy of 5-aminosalicylate preparations. Immunopharmacology 1993;2:277-287.
Bjarnason I, Macpherson AJ.
Sulphasalazine and new 5-aminosalicylic acids in inflammatory bowel
disease. Hospital Update Plus 1993;19:60-61.
Bjarnason I, Macpherson A,
Somasundaram S, Hayllar J. Lower bowel toxicity of nonsteroidal
anti-inflammatory drugs. In: Lewis, Furst D, ed. Nonsteroidal
anti-inflammatory drugs: Mechanisms and clinical uses (2 nd ed) New
York: Marcel Dekker, 1993: 145-157.
Bjarnason I, Macpherson A,
Somasundaram S, Teahon K. Nonsteroidal anti-inflammatory drugs and
inflammatory bowel disease. Can J Gastroenterol 1993;7:160-169
1992
Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut. 1992;33:320-323.
Bjarnason I, Smethurst P,
Macpherson A, Walker F, McElnay JC, Passmore AP, Menzies IS,. Glucose
and citrate reduce the permeability changes caused by indomethacin in
humans. Gastroenterology 1992;102:1546-1550.
Bjarnason I, Hayllar J,
Smethurst P, Price AB, Gumpel MJ. Metronidazole reduces inflammation
and blood loss in NSAID enteropathy. Gut 1992;33:1204-1208.
Wassif W, Bjarnason I. A comparison of the effects of aceclofenac and diclofenac on gastrointestinal blood loss. Br J Clin Research. 1992;3:109-114.
Macpherson AJS, Chester KA, Robson L, Bjarnason I,
Malcolm ADB, Peters TJ. Increased expression of C-myc proto-oncogene in
biopsies of ulcerative colitis and Crohn's disease. Gut 1992;33:651-656.
Hayllar J, Macpherson A, Bjarnason I. Gastroprotection and nonsteroidal anti-inflammatory drugs. Rational and clinical implications. Drug Safety. 1992;7:86-105.
Bjarnason I, Fehilly B,
Smethurst P, Menzies IS, Levi AJ. Effects of nonsteroidal
antiinflammatory drugs on permeability of the small intestine in
humans. J Rheumatol 1992;19 (Suppl 36):83-84.
Macpherson AJ, Bjarnason I, Forgacs IC. Discovery for the gene for familial adenomatous polyposis. Br Med J. 1992;304:858-859.
1991
Bjarnason I, Fehilly B,
Smethurst P, Menzies IS, Levi AJ. The importance of local versus
systemic effects of non-steroidal anti-inflammatory drugs to increase
intestinal permeability in man. Gut. 1991;32:275-277.
Bjarnason I, Smethurst P,
Menzies IS, Peters TJ. The effect of polyacrylic acid polymers
(carbopol) on small intestinal function and permeability changes caused
by indomethacin. Scand J Gastroenterol. 1991;26:685-688.
Teahon K, Pearson M, Levi AJ, Bjarnason I. Elemental diet in the management of Crohn's disease during pregnancy. Gut. 1991;32:1079-1081.
Teahon K, Smethurst P, Levi AJ, Bjarnason I. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology. 1991;101:84-89.
Duane P, Teahon K, Crabtree JE, Levi AJ, Heatley RV, Bjarnason I.
The relationship between nutritional status and serum soluble
interleukin-2 receptor concentrations in patients with Crohn's disease
treated with elemental diet. Clinical Nutrition. 1991;10:222-227.
Bjarnason I, Rooney PJ. NSAID enteropathy-Not just a pain in the gut. J Rheumatology. 1991;18:796-798.
Bjarnason I. Bowel bears brunt of NSAID insult. Hospital Doctor 1991;11:20-21.
Teahon K, Bjarnason I, Levi AJ.
The role of enteral and parentral nutrition in Crohn's disease and
ulcerative colitis. Progress in inflammatory disease. 1991;11:1-8.
Bjarnason I. The significance of NSAID damage to the small intestine. Geriatric Medicine. 1991;21:12-15.
Bjarnason I. NSAID-Induced damage in the lower bowel. Physician. 1991;21:280-281.
Hayllar J, Bjarnason I. Sulphasalazine in ulcerative colitis; In memorium? Gut 1991;32:462-463.
1990
Bjarnason I, Hopkinson N,
Zanelli G, Prouse P, Gumpel MJ, Levi AJ. The treatment of non-steroidal
anti-inflammatory drug induced enteropathy. Gut. 1990;31:777-780.
Teahon K, Bjarnason I, Pearson M, Levi AJ. Ten years experience with elemental diet in the management of Crohn's disease. Gut. 1990;31:1133-1137.
Marsh MN, Bjarnason I, Ellis A,
Baker R, Peters TJ. Studies of intestinal lymphoid tissue, X-HLA
status, mucosal morphology, permeability and epithelial lymphoid
populations in first degree coeliac sprue relatives. Gut. 1990;31:32-36.
Levi S, DeLacey G, Price AB, Gumpel MJ, Levi AJ, Bjarnason I.
'Diaphragm like' strictures of the small bowel in patients treated with
non-steroidal anti-inflammatory drugs. Br J Radiol 1990;63:186-189.
Smith T, Bjarnason I.
Experience with the use of a gastrointestinal marker (51CrCl3) in a
combined study of ileal function using 75SeHCAT and 58CoVitB12 measured
by whole body counting. Gut. 1990;31:1120-1125.
Bjarnason I. Experimental evidence of the benefit of misoprostol beyond the stomach in humans. J Rheumatol 1990;17 (Suppl 20):38-41.
Bjarnason I. NSAID induced
enteropathy. In: Peters TJ, ed. The cell biology of inflammation in
the gastrointestinal tract. Hull: Corners publications, 1990: 345-360.
Bjarnason I. Intestinal
permeability barriers. In: Peters TJ, ed. The cell biology of
inflammation in the gastrointestinal tract. Hull: Corners
Publications, 1990: 127-142.
Bjarnason I, Fehilly B,
Smethurst P, Levi AJ. The importance of local versus systemic effects
of NSAIDs to increase small intestinal permeability. Br J Rheumatol
1990;27 (Suppl 2):112-113.
Bjarnason I. NSAIDs: More than just a pain in the stomach. Arthritis in focus. 1990;1:2-3.
Bjarnason I. NSAID risk lies beyond duodenum. Doctor 1990;8th Nov:29.
1989
Bjarnason I, Smethurst P, Fenn
GC, Lee CF, Menzies IS, Levi AJ. Misoprostol reduces indomethacin
induced changes in human small intestinal permeability. Dig Dis Sci.
1989;34:407-411.
Scadding G, Bjarnason I, Brostoff J, Levi AJ, Peters TJ. Intestinal permeability to 51CrEDTA in food intolerant patients. Digestion. 1989;42:104-109.
Bjarnason I, Peters TJ. Intestinal permeability, NSAID enteropathy and inflammatory bowel disease. Gut 1989;30:22-28.
Lambert MT, Bjarnason I, Connelly J, et al. Small intestinal permeability in schizophrenia. Br J Psychiatry 1989;155:619-622.
Teahon K, Bjarnason I. Peptic ulcer disease. Care of the elderly. 1989;1:132-134.
Bjarnason I, Smethurst P,
Clarke P, Menzies IS, Levi AJ, Peters TJ. Effect of prostaglandins on
indomethacin induced increased intestinal permeability in man. Scand J
Gastroenterol 1989;29 (Suppl 164):97-103.
Bjarnason I, Macpherson AJ. The
changing side effect profile of NSAIDs. A new approach for the
prevention of a new problem. Scand J Gastroenterol 1989;24 (Suppl
163):56-64.
1988
Bjarnason I, Zanelli G,
Smethurst P, et al. Clinico-pathological features of NSAID induced
small intestinal strictures. Gastroenterology 1988;94:1070-1074.
Bjarnason I, Zanelli G,
Smethurst P, et al. Clinico-pathological features of nonsteroidal
antiinflammatory drug induced small intestinal strictures.
Gastroenterology. 1988;94:1070-1074.
Lang J, Price AB, Levi AJ, Burke M, Gumpel MJ, Bjarnason I.
Diaphragm disease: the pathology of non-steroidal anti-inflammatory
drug induced disease of the small intestine. J Clin Pathol.
1988;41:516-526.
Bjarnason I, Levi S, Smethurst P, Menzies IS, Levi AJ. Vindaloo and you. Br Med J. 1988;297:1629-1631.
Bjarnason I, Teahon K. New
non-steroidal drug therapies in inflammatory bowel disease: facts,
fiction and potential. Internal medicine for the specialist.
1988;9:104-117.
Levi S, Bjarnason I, Swinson
CM, Polak JM, Murray W, Levi AJ. Malignant pancreatic somatostatinoma
in a patient with dermatitis herpetiformis and coeliac disease.
Digestion 1988;39:1-6.
Bjarnason I. Non-steroidal
anti-inflammatory drug induced small intestinal inflammation in man.
In: Pounder R, ed. Recent advances in gastroenterology-7. London:
Churchill Livingstone, 1988: 23-46.
Bjarnason I, Price AB. The effect of NSAIDs on the large intestine. Gastrointestinal futures and clinical practice. 1988;3:7-10.
Peters TJ, Bjarnason I. Uses and abuses of intestinal permeability tests. Can J Gastroenterol 1988;2:127-132.
1987
Bjarnason I, Zanelli G, Smith
T, et al. Nonsteroidal antiinflammatory drug induced intestinal
inflammation in humans. Gastroenterology. 1987;93:480-489.
Raja K, Bjarnason I, Simpson
RJ, Peters TJ. In vitro measurment and adaptive response of iron uptake
by mouse intestine. Cell Biochem Funct. 1987;5:69-76.
Smith T, Bjarnason I, Hesp R.
Critical analyses of a combined test (75SeHCAT and 58CoB12) of ileal
function using a whole body counter. Clin Phys Physiol Meas.
1987;8:159-171.
Bjarnason I, Zanelli G, Prouse
P, et al. Blood and protein loss via small intestinal inflammation
induced by nonsteroidal antiinflammatory drugs. Lancet. 1987;ii:711-714.
Bjarnason I, Zanelli G, Smith
T, et al. The pathogenesis and consequences of NSAID induced small
intestinal inflammation. Scand J Rheumatol. 1987;(Suppl 69):55-62.
Bjarnason I, Peters TJ. Helping the mucosa make sense of macromolecules. Gut 1987;28:1057-1061.
1986
Bjarnason I, Marsh MN, Price A,
Levi AJ, Peters TJ. Intestinal permeability in patients with coeliac
disease and dermatitis herpetiformis. Gut. 1986;26:1214-1219.
Bjarnason I, Williams P,
Smethurst P, Peters TJ, Levi AJ. The effect of NSAIDs and
prostaglandins on the permeability of the human small intestine. Gut.
1986;27:1292-1297.
Zanelli G, Bjarnason I, Smith
T, Crawley JC, Levi AJ, Copeland RI. Technetium-99m labelled porphyrin
as an imaging agent for occult infections and inflammation. Nuclear Med
Commun. 1986;7:17-24.
Maxton DG, Bjarnason I,
Reynolds AP, Catt SD, Peters TJ, Menzies IS. Lactulose, 51CrEDTA,
L-rhamnose and polyethylene glycol 400 as probe markers for "in vivo"
assessment of human intestinal permeability. Clin Sci. 1986;71:71-80.
Macpherson AJM, Bjarnason I,
Peters TJ. The subcellular distribution and levels of calmodulin in
jejunal biopsies from control subjects and patients with coeliac
disease. Clin Chim Acta 1986;159:133-138
Zanelli G, Bjarnason I, Ellison
D, Levi AJ. New radiosotope tests: new gastrointestinal diseases. In:
Malagutty P, Scigaretta G, Abbati A, Furno A, ed. New radioisotope
tests in gastroenterology. Italia: Masson, 1986: 75-81.
Bjarnason I, Peters TJ, Levi AJ. Intestinal permeability; clinical correlates. Dig Dis 1986;4:83-92.
Bjarnason I, Smethurst P, Levi
AJ. Measurment of intestinal permeability with special reference to
51CrEDTA. In: Malgutty P, Scigaretta G, Abbati A, Furno A, ed. New
radioisotope tests in gastroenterology. Italia: Masson, 1986: 480-489.
Bjarnason I, Zanelli G, Prouse
P, Williams P, Gumpel MJ, Levi AJ. The effect of NSAIDs on the human
small intestine. Drugs. 1986;32 (Suppl1):35-41.
Zanelli G, Bjarnason I, Smith
T, Crawley J, Levi AJ. 99mTc-labelled synthetic porphyrins for the
localization of occult infection and inflammation. In: Nicolini M,
Bandoli G, Mazzi U, ed. Technettium in chemistry and nuclear
medicine. Raven Press, 1986: (vol 2):249-252
1985
Bjarnason I, Smethurst P, Levi
AJ, Peters TJ. Intestinal permeability to 51CrEDTA in rats with
experimentally induced enteropathy. Gut. 1985;26:579-585.
Patel EK, Bruce SE, Bjarnason I,
Peters TJ. Rat gastrointestinal transglutaminase: demonstration of
enzyme activity and cell and tissue distribution. Cell Biochem Funct.
1985;3:199-203.
Bjarnason I, Goolamali SK, Levi AJ, Peters TJ. Intestinal permeability in patients with atopic eczema. Br J Dermatol. 1985;112:291-297.
Bruce SE, Bjarnason I, Peters
TJ. Human jejunal transglutaminase: demonstration of activity, enzyme
kinetics and substrate specifity with special relation to gliadin and
coeliac disease. Clin Sci 1985;68:573-579.
Peters TJ, Bjarnason I. Intestinal permeability. In: Hunter JO, Allin-Jones V, ed. Food and the gut. Oxford: Balliere Tindall, 1985: 30-44
1984
Bjarnason I, Peters TJ. In
vitro determination of intestinal permeability: Demonstration of a
persisting defect in patients with coeliac disease. Gut.
1984;25:145-150.
Bjarnason I, Cotes M, Knowles
S, Reed S, Peters TJ. Giant lymph node hyperplasia (Castleman's
disease) of the mesestery. Observations on the associated anaemia.
Gastroenterology. 1984;87:216-223.
Bjarnason I, Ward K, Peters TJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet. 1984;i:179-182.
Bjarnason I, Williams P, So A,
et al. Intestinal permeability and inflammation in rheumatoid
arthritis; effects of non-steroidal anti-inflammatory drugs. Lancet
1984;ii:1171-1174.
Peters TJ, Bjarnason I.
Biochemical approach to the investigation of intestinal disease. In:
Batt RM, Lawrence TJL, ed. Function and dysfunction of the small
intestine. Liverpool: Liverpool University Press, 1984: 199-218.
Peters TJ, Bjarnason I. Coeliac syndrome: biochemical mechanisms and the missing peptidase hypothesis revisited. Gut. 1984;25:913-918.
1983
Bjarnason I, Jonsson S, Hardarsson T. Cardiac arrhythmias in hypertrophic cardiomyopathy. Br Heart J. 1982;48:198-203.
Bjarnason I, Peters TJ, Veall
N. A persistent defect of intestinal permeability in coeliac disease as
demonstrated by a 51Cr-labelled EDTA absorption test. Lancet.
1983;i:323-325.
Bjarnason I, O'Morain C, Levi AJ, Peters TJ. The absorption of 51Cr EDTA in inflammatory bowel disease. Gastroenterology 1983;85:318-322.
Peters TJ, Bjarnason I.
Membrane disorders: a new approach to their study in man. In: Masson M,
ed. Biologie Prospective. Paris: Pont-A-Mousson, 1983: 909-920.
1982
Bjarnason I, Magnusson B, Bjornsson S. Idiopathic chronic active hepatitis in Iceland. Acta Med Scand. 1982;211:305-307.
Bjarnason I, Jonsson S,
Hardarsson T. The mode of inheritance of hypertrophic cardiomyopathy in
Iceland: An echocardiographic study. Br Heart J. 1982;47:122-129.
1981
Bjarnason I, Magnusson B, Bjornsson S. The significance of histologic chronic active hepatitis in Iceland. Icelandic Med J 1981;67:193-194.
Bjarnason I, Bjornsson S. Oesophageal ulcers. Acta Med Scand 1981;209:431-432.
Bjarnason I, Jonsson S, Hardarson T. Hypertrophic cardiomyopathy. A clinical and echocardiographic study. Icelandic Med J. 1981;67:99-105.
Bjarnason I, Jonsson S,
Hardarson T. 24 hour electrographic monitoring in patients with
hypertrophic cardiomyopathy. Icelandic Med J. 1981;67:216-221
1980
Bjarnason I, Hallgrimsson J. Hypertrophic cardiomyopathy. An autopsy study of the years 1966-1978. Icelandic Med J. 1980;66:205-208